News | Regulatory news

Accelerating development of RP501 first-line therapy for dry eye disease

Redwood Pharma AB (publ) Quarterly report January–June 2021

Phase II results published in medical journal and Redwood Pharma to present poster at medical meeting

Redwood Pharma will receive approximately SEK 34.2 million through a heavily oversubscribed rights issue

Redwood Pharma to provide digital presentations in connection with the rights issue

Redwood Pharma announces intention to move to Nasdaq First North Growth Market stock exchange


Supplementary analyses to topline Phase II results reveal additional RP101 clinical strengths

Redwood Pharma to present at Aktiespararnas Stora Aktiedagen Digitalt in Stockholm on November 30, 2020

RP501: Redwood Pharma makes official name for mild dry eye therapeutic development program

Redwood Pharma launches new development program for mild dry eye based on its proprietary IntelliGel platform

Quarterly Report January–June 2020

New patent for the use of estrogens in the treatment of DED to be issued in the US

Video interview with CEO Martin Vidaeus – Positive Redwood Pharma status

Redwood Pharma secures bridge financing and issues warrants

Redwood Pharma will receive approximately SEK 2.1 million

Quarterly report January – March 2020

Live Webcast of the announcement of RP101 Phase II clinical results

RP101 Phase II clinical results

Redwood Pharma to present at BIO-Europe Spring

Redwood Pharma AB (publ) Year-end report 2019

Patent to be granted in China regarding IntelliGel


Video presentation (ENG) of clinical status of RP101 by CEO Martin Vidaeus

Redwood Pharma arranging partnering meetings during JPMorgan Healthcare Conference 2020 in San Francisco

Redwood Pharma AB Quarterly Report January – September 2019

Redwood Pharma to present at BioStock Live in Stockholm on December 3, 2019

Last patient completes treatment in RP101 Phase II clinical trial

Redwood Pharma to attend BIO-Europe Nov. 10-12 in Hamburg

Redwood Pharma to present at BioStock Live in Stockholm on August 27, 2019

Last patient recruited in Redwood Pharma Phase II trial

Update regarding financial situation

Update regarding RP101 Phase II trial

Redwood Pharma to Attend BIO-Europe 2019, Mar. 25 – 27 in Vienna for Partnering Discussions

First patient treated in Redwood Pharma Phase II study

Redwood Pharma receives its third and last national approval


Redwood Pharma receives approval from another drug authority – the Austrian

Redwood Pharma initiates clinical trial

New patent for IntelliGel on the way in the EU

Redwood Pharma to Attend BIO-Europe 2018, Nov. 5 – 7 in Copenhagen for Partnering Discussions

Redwood Pharma to present at Nordic Life Science Days in Stockholm on September 11, 2018

Interim Report January – June 2018

Come meet us when Redwood Pharma presents

Redwood Pharma has submitted an application for the start of clinical trial

Video Presentation (ENG) by Redwood Pharma June 11, 2018

Redwood Pharma to present at NLSDays in Stockholm, Sep. 10-12, 2018

Redwood Pharma’s new rights issue oversubscribed

Redwood Pharma to execute New Rights Issue and takes important step in securing further financing

Redwood Pharma acquires intellectual property rights

Asian Pharmaceutical Firm to Evaluate IntelliGel®

Positive meeting with Medical Products Agency prior to clinical Phase II trial

Additional US patent to be granted regarding IntelliGel

Redwood Pharma to Attend BIO-Europe 2018, Mar. 11 – 14 in Amsterdam for Partnering Discussions


Interview with CEO: Development throught toxicology and safety studies

Redwood Pharma starts production of RP101 for clinical trials

Toxicology and Safety Studies are Successfully Completed

Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 – 8 in Berlin for Partnering Discussions

Redwood Pharma enters into agreement with CRO for clinical trial

Redwood Pharma begins production of active ingredient in RP101 for Phase II studies

Redwood Pharma initiates toxicological safety studies

New US patent approved

Redwood Pharma AB (publ) End of Year Report 2016

Eye expert to support Redwood Pharma

Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies


Development of Redwood Pharma’s RP101 ophthalmic therapy continues according to plan along with value-enhancing networking

Redwood Pharma AB (publ) to present at Aktiespararna conference in Örebro on November 19, 2016

Redwood Pharmas IntelliGel drug delivery platform demonstrates positive results in in vitro test

Redwood Pharma AB appoints Ulf Björklund as Chief Medical Officer

Market Trends Highlighted in Tear Film and Ocular Surface (TFOS) Conference in Montpellier Confirm Need for Redwood Pharmas Dry Eye Therapy

Japanese patent granted for IntelliGel platform

Redwood Pharma to present at French-Swedish Life Science Day 2016

Redwood Pharma to attend leading conference on ocular tear film science

Redwood Pharma attending OIS-ASRS Conference in San Francisco

Redwood Pharma to Present at BIO 2016 in San Francisco

Redwood Pharma raises SEK 6.6 million in private placement


Redwood Pharma licenses novel hydrogel drug delivery technology from Broda Technologies

Latest presentation

Redwood Pharma – Interview with CEO

Latest report